Celldex reports Q2 results; barzolvolimab Phase 3 data expected 2026
Celldex reported Q2 financial results, with Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria completed six months ahead of schedule.
View filing at SEC.gov →2 most recent filings and news items mentioning CLDX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/CLDX/news?limit=20"
Pull CLDX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayCelldex reported Q2 financial results, with Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria completed six months ahead of schedule.
View filing at SEC.gov →Celldex Therapeutics filed an amendment to its 2021 Omnibus Equity Incentive Plan, expanding available stock by 3.4 million shares. This adjustment impacts future employee retention and compensation structures.
View filing at SEC.gov →